Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein

J. Hurnakova, H. Hulejova, J. Zavada, M. Komarc, LA. Cerezo, H. Mann, J. Vencovsky, K. Pavelka, L. Senolt,

. 2018 ; 37 (8) : 2055-2062. [pub] 20180414

Language English Country Germany

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 1997-01-01 to 1 year ago

Approximately half of patients with rheumatoid arthritis (RA) have normal C-reactive protein (CRP) levels. Calprotectin is a promising and likely more specific biomarker of disease activity than conventionally used acute phase reactants. We aimed to analyse the levels of serum calprotectin in RA patients with clinically active disease and with normal/low CRP. A total of 160 RA patients underwent clinical examination (DAS28-ESR and CDAI). The levels of calprotectin were analysed in patients with moderate to high disease activity with normal/low CRP levels and in 32 healthy subjects. The discriminatory capacity of calprotectin to identify clinically active patients in spite of normal/low CRP was assessed using ROC curves. Out of all RA patients, 74/160 (46.3%) were in remission or had low disease activity according to DAS28 and had normal/low CRP levels. However, 51/160 (32%) had normal/low CRP levels despite having moderate to high disease activity. In these patients, calprotectin levels were significantly higher than those in patients who had normal/low CRP and were in remission or showed low disease activity (2.7 ± 1.5 vs. 2.1 ± 1.2 μg/mL, p = 0.043), which differed from those in healthy subjects (2.7 ± 1.5 vs. 1.9 ± 1.2 μg/mL, p = 0.011). The discriminatory capacity for calprotectin to distinguish clinically active vs. inactive disease despite normal/low CRP using AUC of the DAS28 was 0.607 (95% CI 0.503 to 0.711, p = 0.043). The present study demonstrates that calprotectin may reflect inflammatory activity in RA patients where CRP fails to do so.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012722
003      
CZ-PrNML
005      
20220111131706.0
007      
ta
008      
190405s2018 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s10067-018-4091-5 $2 doi
035    __
$a (PubMed)29656372
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Hurňáková, Jana $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. $7 xx0268288
245    10
$a Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein / $c J. Hurnakova, H. Hulejova, J. Zavada, M. Komarc, LA. Cerezo, H. Mann, J. Vencovsky, K. Pavelka, L. Senolt,
520    9_
$a Approximately half of patients with rheumatoid arthritis (RA) have normal C-reactive protein (CRP) levels. Calprotectin is a promising and likely more specific biomarker of disease activity than conventionally used acute phase reactants. We aimed to analyse the levels of serum calprotectin in RA patients with clinically active disease and with normal/low CRP. A total of 160 RA patients underwent clinical examination (DAS28-ESR and CDAI). The levels of calprotectin were analysed in patients with moderate to high disease activity with normal/low CRP levels and in 32 healthy subjects. The discriminatory capacity of calprotectin to identify clinically active patients in spite of normal/low CRP was assessed using ROC curves. Out of all RA patients, 74/160 (46.3%) were in remission or had low disease activity according to DAS28 and had normal/low CRP levels. However, 51/160 (32%) had normal/low CRP levels despite having moderate to high disease activity. In these patients, calprotectin levels were significantly higher than those in patients who had normal/low CRP and were in remission or showed low disease activity (2.7 ± 1.5 vs. 2.1 ± 1.2 μg/mL, p = 0.043), which differed from those in healthy subjects (2.7 ± 1.5 vs. 1.9 ± 1.2 μg/mL, p = 0.011). The discriminatory capacity for calprotectin to distinguish clinically active vs. inactive disease despite normal/low CRP using AUC of the DAS28 was 0.607 (95% CI 0.503 to 0.711, p = 0.043). The present study demonstrates that calprotectin may reflect inflammatory activity in RA patients where CRP fails to do so.
650    _2
$a revmatoidní artritida $x krev $7 D001172
650    _2
$a biologické markery $x krev $7 D015415
650    _2
$a krevní sedimentace $7 D001799
650    _2
$a C-reaktivní protein $x analýza $7 D002097
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a leukocytární L1-antigenní komplex $x krev $7 D039841
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a referenční hodnoty $7 D012016
650    _2
$a stupeň závažnosti nemoci $7 D012720
651    _2
$a Finsko $7 D005387
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hulejova, Hana $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
700    1_
$a Zavada, Jakub $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
700    1_
$a Komarc, Martin $u Department of Methodology, Faculty of Physical Education and Sport, Charles University in Prague, Czech Republic, José Martího 31, 162 52, Prague 6, Czech Republic.
700    1_
$a Cerezo, Lucie Andres $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
700    1_
$a Mann, Herman $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
700    1_
$a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
700    1_
$a Pavelka, Karel $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic.
700    1_
$a Senolt, Ladislav $u Institute of Rheumatology, Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. senolt@revma.cz. Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Czech Republic, Na Slupi 4, 120 50, Prague 2, Czech Republic. senolt@revma.cz.
773    0_
$w MED00001162 $t Clinical rheumatology $x 1434-9949 $g Roč. 37, č. 8 (2018), s. 2055-2062
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29656372 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20220111131701 $b ABA008
999    __
$a ok $b bmc $g 1392032 $s 1051027
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 37 $c 8 $d 2055-2062 $e 20180414 $i 1434-9949 $m Clinical rheumatology $n Clin Rheumatol $x MED00001162
LZP    __
$a Pubmed-20190405

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...